Open7.600 | Close7.290 |
Vol / Avg.1.702M / 1.102M | Mkt Cap428.771M |
Day Range7.050 - 7.600 | 52 Wk Range5.890 - 29.523 |
Replimune Group Stock (NASDAQ: REPL) stock price, news, charts, stock research, profile.
Open7.600 | Close7.290 |
Vol / Avg.1.702M / 1.102M | Mkt Cap428.771M |
Day Range7.050 - 7.600 | 52 Wk Range5.890 - 29.523 |
Q3 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.860 | -0.900 | -0.0400 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-12-06 | Barclays | Peter Lawson | Maintains | OverweightOverweight | Lowers | 50.00 | 13.00 |
2023-11-13 | HC Wainwright & Co. | Robert Burns | Maintains | BuyBuy | Lowers | 50.00 | 48.00 |
2023-11-08 | Wedbush | Robert Driscoll | Reiterates | OutperformOutperform | Maintains | - | 52.00 |
2023-08-07 | HC Wainwright & Co. | Robert Burns | Maintains | BuyBuy | Lowers | 51.00 | 50.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
REPL | Replimune Group | -4.47% | 428.8M |
SPRY | ARS Pharmaceuticals | 0.57% | 504M |
BLUE | bluebird bio | -39.5% | 318.2M |
CELC | Celcuity | -0.34% | 373M |
KRRO | Korro Bio | 4.19% | 396.6M |
You can purchase shares of Replimune Group (NASDAQ: REPL) through any online brokerage.
Other companies in Replimune Group’s space includes: ARS Pharmaceuticals (NASDAQ:SPRY), bluebird bio (NASDAQ:BLUE), Celcuity (NASDAQ:CELC), Korro Bio (NASDAQ:KRRO) and LianBio (NASDAQ:LIAN).
The latest price target for Replimune Group (NASDAQ: REPL) was reported by Barclays on Wednesday, December 6, 2023. The analyst firm set a price target for 13.00 expecting REPL to rise to within 12 months (a possible 79.06% upside). 17 analyst firms have reported ratings in the last year.
The stock price for Replimune Group (NASDAQ: REPL) is $7.26 last updated December 8, 2023 at 11:41 PM UTC.
There is no dividend information for Replimune Group.
Replimune Group’s Q3 earnings are confirmed for Thursday, February 8, 2024.
There is no upcoming split for Replimune Group.
Replimune Group is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.